Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Still Yearning for Baxalta, Shire Snaps Up Dyax in $5.9 Billion Deal

Dublin-based Shire (SHPG) announced today that it will acquire Burlington, Mass.-based Dyax Corporation (DYAX) for about $5.9 billion. Shire will pay $37.30 per Dyax share in cash, totaling around $5.9 billion. In addition, if Dyax’s pipeline product, DX-2930 for the treatment of HAE, a rare, debilitating genetic inflammatory condition, is approved, Dyax shareholders will receive […]

Read More »

Vertex Pharma receives subpoena from Department of Justice

Vertex Pharmaceuticals Inc said it received a subpoena from the U.S. Department of Justice in the third quarter related to its marketed medicines, seeking documents related primarily to its “good laboratory practices” in a bioanalytical lab. Good laboratory practices are rules that govern non-clinical safety studies, ensuring quality, integrity and reliability of data. Bioanalytical labs […]

Read More »

Arcturus Therapeutics Stands to Collect Up to $1.66 Billion from Rare Disease Pact with Ultragenyx

Novato, Calif.-based Ultragenyx Pharmaceutical Inc. (RARE), announced today that it has inked a research and collaboration deal with San Diego-based Arcturus Therapeutics, Inc.   The two companies will work to identify and develop messenger RNA (mRNA) therapeutics for rare disease targets utilizing Arcturus’ UNA Oligomer chemistry and LUNAR nanoparticle delivery program. Ultragenyx will pay Arcturus […]

Read More »

Amgen profit beats Street, issues conservative 2016 forecast

Amgen Inc (AMGN.O) on Wednesday reported much higher-than-expected third-quarter profit, helped by a 30-percent spike in revenue from the rheumatoid arthritis drug Enbrel due to price increases and inventory stocking. The world’s largest biotechnology company raised its full-year earnings forecast on the back of the strong quarter, and issued its first 2016 projections for adjusted […]

Read More »

Sanofi U.S. recalls Auvi-Q injections for severe allergy

French drugmaker Sanofi SA said it was voluntarily recalling all its Auvi-Q injections in the United States to treat patients with severe allergic reactions. The company said on Wednesday its U.S. unit was recalling the injections as they could potentially deliver an inaccurate dose. Auvi-Q is designed to treat anaphylaxis, a potentially fatal allergic reaction, […]

Read More »

Gilead hepatitis C drug sales trend flattens, shares dip

Gilead Sciences Inc on Tuesday said its quarterly profit rose 70 percent, but sales growth for its hepatitis C drugs flattened as health insurers limited access to the expensive treatments. Shares of the biotechnology company fell slightly. Gilead’s quarterly product sales rose 37 percent to $8.2 billion. Sales of hepatitis C drugs Sovaldi and Harvoni […]

Read More »

Macrocure’s cell therapy for wounds fails late study

Israeli biotechnology company Macrocure Ltd said it would “analyze all strategic options” after its cell therapy for hard-to-treat wounds failed a late-stage U.S. study, pushing its shares down more than 50 percent after the bell. Macrocure’s CureXcell, already in use in Israel, is a formulation of living human white blood cells activated to stimulate the […]

Read More »

FDA approves Amgen’s injected immunotherapy for melanoma

U.S. health regulators on Tuesday approved Amgen Inc’s novel cancer immunotherapy for injection into melanoma lesions and lymph nodes of patients with the deadliest form of skin cancer that returns after initial surgery. The drug, to be sold under the brand name Imlygic, is an engineered version of a herpes virus that kills cancer cells […]

Read More »

Shire to resubmit dry-eye disease drug to FDA with new study data

London-listed pharma firm Shire said its dry-eye disease drug lifitegrast significantly improved patient symptoms in a new study, supporting a re-submission of the potentially block-busting medicine to U.S. regulators early next year. Shares in Shire jumped more than 6 percent after it announced the positive results of the study on Tuesday. They were trading up […]

Read More »

Bio Blast Pharma reports promising data on muscle wasting drug

Bio Blast Pharma Ltd said its lead experimental drug showed signs of being effective in treating patients with a rare muscle wasting disorder, besides also hitting the main goals of safety and tolerability. The company said the experimental drug, Cabaletta, hit multiple efficacy endpoints during a mid-stage trial on patients suffering from oculopharyngeal muscular dystrophy, […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom